| [1] |
Luo Yuxin, Yin Fengrong, Zhang Xiaolan.
Interpretation of European Association for study of liver recommendations on treatment of hepatitis C 2015
[J]. Clinical Focus, 2016, 31(3): 322-324.
|
| [2] |
.
[J]. Clinical Focus, 2015, 30(9): 1070-1072.
|
| [3] |
Tan Guolei;Sun Mei;Wang Jianfang;Wu Xuping.
Distribution characteristics of hepatitis C virus genotyping in Nanjing area
[J]. Clinical Focus, 2015, 30(4): 393-396.
|
| [4] |
.
[J]. Clinical Focus, 2011, 26(24): 2184-2185.
|
| [5] |
.
[J]. CLINICAL FOCUS, 2010, 25(9): 810-811.
|
| [6] |
.
[J]. CLINICAL FOCUS, 2009, 24(21): 1922-1924.
|
| [7] |
DENG Lin-yu;LIU Feng-jun;YANG Jia-hong;LIU Cong;TANG Hong.
Analysis of serum hepatitis C virus,anti-HCV and alanine transaminase:resuits from patients with hepatitis C
[J]. CLINICAL FOCUS, 2008, 23(22): 1600-1603.
|
| [8] |
.
[J]. CLINICAL FOCUS, 2007, 22(24): 1795-1796.
|
| [9] |
.
[J]. CLINICAL FOCUS, 2007, 22(16): 1203-1204.
|
| [10] |
.
[J]. CLINICAL FOCUS, 2007, 22(7): 0-0.
|
| [11] |
.
[J]. CLINICAL FOCUS, 2007, 22(7): 504-505.
|
| [12] |
.
[J]. CLINICAL FOCUS, 2006, 21(3): 220-222.
|
| [13] |
.
[J]. CLINICAL FOCUS, 2005, 20(16): 939-0.
|
| [14] |
.
Polymerase chain reaction and hybrid ELISA to observe the effect of combination therapy of IL-2 and IFN-α for chronic hepatitis C
[J]. CLINICAL FOCUS, 2004, 19(7): 361-364.
|
